Brookfield Infrastructure (BIPC.TO) traded up 0.02 % during a 24 hours period ending at 11:49 PM Central Europe on Tuesday 27th. One Brookfield Infrastructure stock can currently be bought for about CAD 51.94 on popular exchanges. Current supply of Brookfield Infrastructure stocks is 122.9 mn. Brookfield Infrastructure has a current market capitalization of CAD 6.4 bn and approximately CAD 12.4 mn worth of Brookfield Infrastructure was traded on exchanges in the last 24 hours. Since last month end, Brookfield Infrastructure has traded 5.47 % up. Simple moving average of last 200 days is at CAD 57.11. The highest price of past 52 weeks was recorded at CAD 70.05 on 02/12/2026. 52 weeks low was at CAD 46.74 on 04/29/2026.
Here is how related stocks have performed in the past 24 hours:
Cg Oncology (CGON) traded down -0.24 % and now trades at USD 62.94. Current market capitalisation for Cg Oncology is USD 5.5 bn.
Cogent Biosciences (COGT) traded down -0.96 % and now trades at USD 32.01. Current market capitalisation for Cogent Biosciences is USD 5.4 bn.
Ormat (ORA) traded up 0.05 % and now trades at USD 92.03. Current market capitalisation for Ormat is USD 5.4 bn. Ormat has a current price to earnings ratio of 42.55. ORMAT TECHNOLOGIES INC reported strong performance in the first half of fiscal 2027. The company added the largest number of desks in a single quarter, expanding its operational capacity to more than 145 000 across 85 centres in eight cities. Occupancy rose to around 84 %, with mature locations achieving high utilisation. Revenue grew, driven by both core desk sales and an accelerating services and digital platform. EBITDA and profit margins expanded, reflecting improved operating leverage. Cash generation remained robust, sufficient to fund the current investment cycle and leave surplus for future growth. Management highlighted the resilience of branded workspaces in an evolving market and reaffirmed its focus on expanding capacity and enhancing service offerings.
Haemonetics /Mass (HAE) traded up 0.57 % and now trades at USD 119.97. Haemonetics /Mass has a market capitalisation of USD 5.4 bn. Current price/earnings ratio for Haemonetics /Mass is 57.62. Pharming Group N.V. reported a strong third‑quarter performance, with revenue growth driven primarily by its rare‑disease therapies. Sales of the acute HAE treatment rose, reflecting stabilised U.S. demand, while the APDS therapy expanded internationally, benefiting from new launches in Germany and Japan and a pediatric label approval in the United States. The company also announced encouraging Phase II data for its PI3Kδ inhibitor in broader primary immunodeficiency populations, with a further report expected in November. Financially, operating profit increased substantially, and cash from operations strengthened the balance sheet. Pharming confirmed its guidance for the full year, targeting slightly higher revenues and maintaining a disciplined expense profile while advancing its pipeline and preparing for potential expansion into larger patient groups.
New Jersey (NJR) traded up 0.06 % and now trades at USD 53.12. Current market capitalisation for New Jersey is USD 5.4 bn. New Jersey has a current price to earnings ratio of 14.69.